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Background: This study was designed to assess the diagnostic value and clinical benefits of lumbar zygapophyseal
joint injections in patients with chronic lower back pain.
Methods: Two hundred and seventy-seven patients (136 males and 141 females, aged 15–82 years) with chronic
lower back pain were enrolled in the trial and met the following criteria: pain for more than 1 year; no root signs;
and no history of back surgery. Under fluoroscope, a 0.8–1.5 mL mixture of lidocaine, betamethasone dipropionate
and iopamidol (1:1:0.5) was injected into each joint after intra-articular localization of the needle tip was confirmed.
A questionnaire with a pain scale was administered immediately or the day after injection, and then after 1, 3,
6 and 12 weeks. Partial arthrograms were reviewed by a radiologist.
Results: Four hundred and forty-nine joint injections were performed in 277 patients (L3–4, n = 76; L4–5, n = 272;
L5–S1, n = 101). Bilateral injections were performed in 117 patients (42.2%). The study group comprised 204 patients
(73.6%) with an excellent or good response, whereas the control group comprised the remaining 73 patients
(26.4%). The rates of good response in the study group were 72.1% (147/204) after 3 weeks, 40.7% (83/204)
after 6 weeks, and 31.4% (64/204) after 12 weeks. Partial arthrograms revealed 25 patients (9.0%) with synovial
cysts (L3–4, n = 3; L4–5, n = 14; L5–S1, n = 8); 23 of these patients (92.0%) had a good response to the injections.
Five of the 6 patients with spondylolysis (83.3%), having abnormal communication between the injected and contiguous
joint, had a good response to the injections. The abovementioned, abnormal partial-arthrogram findings correlated
significantly with the rate of good response to the injections. Although 3 patients had contrast medium extravasated
into the epidural space during injection, none of the 277 patients had deteriorating lower back pain after the injections.
Conclusion: Lumbar zygapophyseal joint injections, as a useful diagnostic tool for facet joint syndrome, could also
have useful palliative effects in the management of chronic lower back pain. [J Chin Med Assoc 2005;68(2):59–64]
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Introduction
The lumbar zygapophyseal joints, conveniently called
lumbar facet joints, are some of the areas potentially
affected in lower back pain.1–3 Indeed, lower back pain
originating from zygapophyseal joints is a kind of
somatic pain and can radiate to the lower extremities.
It may easily be confused with radicular pain, which
results primarily from disk problems, and cannot be
differentiated from other kinds of somatic pain of
discogenic or other origin.3 There are no noninvasive
radiographic or clinical examinations to identify the
zygapophyseal joints as sources of lower back pain.
Analgesia from injection of anesthetics into the
zygapophyseal joints or their nerve supplies has been
accepted as the standard for diagnosing zygapophyseal
joint pain,4–9 and has also been accepted as providing
partial or complete therapeutic relief of lower back
pain. Here, we present a study of lumbar zygapophyseal
joint injections, combined with partial arthrography,
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to assess the diagnostic value and clinical benefits in
patients with chronic lower back pain.
Methods
Study participants
Study participants were selected consecutively from
patients in our outpatient department with the principal
complaint of chronic lower back pain. Commonly, the
patients had focal pain, soreness or tenderness of the
lower back, sometimes with referred pain to the lower
extremities. Symptoms occurred intermittently and
were often associated with trigger points or postures.
The duration of lower back pain varied from 1 year to
more than 20 years. Because of the long duration and
complexity of symptoms, clinical histories were hard
to trace precisely, and the triggering time or cause of
lower back pain was difficult to define in most patients.
However, all patients had a clinician-assessed history
of lower back pain for more than 1 year. Patients were
excluded for the following reasons: root signs, neural
compression problems evident from previous imaging
studies, if available, previous back surgery, or a history
of inflammatory arthritides or spondyloarthropathies.
Injection procedure
The lumbar zygapophyseal joint selected for injection
was matched to the patient’s subjective orientation
of maximal symptoms, according to the mapping of
pain-referral patterns in symptomatic patients by
Mooney and Robertson.1 Bilateral zygapophyseal joint
injections were related to patient self-complaints of
pain. If such complaints were ambiguous in terms of
positioning, we preferred to inject the 2 contiguous
joints. Before the procedure, plain X-ray films of the
lumbar spine, including anteroposterior and lateral
projections, were reviewed to determine the exact
lumbar level of injections, and to ensure there was no
vertebral bone disease. Patients were placed in the
prone position with a pillow under the belly. After
local aseptic and anesthetic procedures, the zyga-
pophyseal joint was approached posteriorly with a
23-gauge spinal needle under fluoroscope.9,10 When
the needle tip was advanced to touch the bone and was
beneath the inferior articular facet of the upper
vertebrae, a test dose of iopamidol (Iopamiro® 370,
Bracco, Italy) was injected to confirm intra-articular
needle localization. A 0.8–1.5 mL mixture of lidocaine,
betamethasone dipropionate (Diprospan®, Schering-
Plough, Heist-op-den-Berg, Belgium) and iopamidol
(1:1:0.5) was then injected into the joint. The injected
volume depended on the pressure sensation of the
injected joint. Posteroanterior spot films of the lumbar
spine after injection were obtained as “partial
arthrograms” (not a direct arthrographic purpose) to
identify distribution of the injected mixture (Figure
1). These procedures and reviews of partial arthro-
grams were done by 1 radiologist.
Pain assessment
A questionnaire with a 10-point visual analogue scale
(VAS) for pain relief was administered to patients
immediately or 1 day after injection, and then at 1,
3, 6 and 12 weeks. The degree of pain relief was
compared with each patient’s subjective description of
pain before and after treatment (Table 1). Excellent or
good responses (VAS score ) 5) to the injections after
1 week suggested that the chronic lower back pain was
of zygapophyseal joint origin, and patients were
included in the study group. Conversely, patients with
fair or poor responses (VAS score * 6) were assumed
to have pain of non-zygapophyseal joint origin and
were included in the control group. Changes in VAS
scores in the study group at 3-, 6-, and 12-week
follow-up visits were self-reported by patients in the
outpatient clinic or by telephone.
Statistical analysis
The Student’s t test and Chi-squared test were used
for statistical analysis. Differences were considered
statistically significant at a p value of less than 0.05.
Percentile values, means, standard deviations, and
prevalence values were obtained using Statistical
Package for the Social Sciences version 11.0 (SPSS
Inc, Chicago, IL, USA).
Figure 1. Spot posteroanterior film for a female patient placed in
the prone position and showing the needle position and a normal
arthrogram of the left L4–5 zygapophyseal joint (arrows). The
arthrogram of the right L4–5 zygapophyseal joint revealed widening
of the joint space and cystic accumulation of the injected mixture
in the superior aspect (arrowhead).
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Results
Patient demographics
Two hundred and seventy-seven patients (136 males
and 141 females, aged 15–82 years) were enrolled in
the study. In total, 449 joint injections were performed
(L3–4, n = 76; L4–5, n = 272; L5–S1, n = 101).
One hundred and thirty-seven patients had 1 injection,
and the remaining 140 had more than 1 injection.
Bilateral injections were performed in 117 patients
(42.2%). The study group comprised 204 patients
(73.6%; 103 males and 101 females; mean age, 45.4 (
11.7 years) with an excellent or good response to
treatment (VAS score ) 5). In the study group, 338
joints were injected (L3–4, n = 59; L4–5, n = 206; L5–
S1, n = 73). Bilateral injections were performed in 85
patients (41.7%). Seventy-three patients (26.4%; 33
males and 40 females; mean age, 48.6 ( 12.7 years;
t = –1.925, p = 0.055) comprised the control group:
43 patients with fair or poor responses to the articular
injections; and 30 with recurring symptoms during the
first week of follow-up. Bilateral injections were
performed in 32 patients (43.8%; r2 = 0.104, p =
0.747). One hundred and eleven joints (L3–4, n =
17; L4–5, n = 66; L5–S1, n = 28) were injected in the
control group. The rates of good response in the study
group were 72.1% (147/204) after 3 weeks, 40.7%
(83/204) after 6 weeks, and 31.4% (64/204) after 12
weeks. Fifty-nine patients (28.9%) in the study group
received radiofrequency rhizotomy; the time between
injections and rhizotomy was 8–313 days (mean,
57.8 ( 18.3 days).
Arthrographic findings
The findings of partial arthrograms were isolated from
clinical responses to the injections. An injection was
considered peri-articular when most of the injected
mixture was coming out of the articular boundary; the
test dose was then resumed at the correct intra-
articular positioning. Peri-articular injections occurred
in 37 of the 277 patients (13.4%), i.e. in 22 of 272
(8.1%) L4–5 joints, and in 15 of 101 (14.9%) L5–S1
joints. There were 26 peri-articular injections in
the study group versus 11 in the control group (12.7%
vs 15.1%; r2 = 0.251, p = 0.617). Abnormal partial
arthrograms included synovial cysts of zygapophyseal
joints, abnormal opacification of another joint, and
extravasation of injected mixture into the epidural
space. Pouch-like accumulation of contrast medium in
the superior aspect of the zygapophyseal joint was
considered to be a synovial cyst (Figure 1). Twenty-
five of the 277 patients (9.0%) had synovial cysts on
partial arthrograms (L3–4, n = 3; L4–5, n = 14; L5–S1,
n = 8); 23 of these patients (92.0%; r2 = 0.416, p <
0.001) had a good response to the injections. Six
patients had abnormal communication between the
injected and contiguous joint (Figure 2). We found
bony defects in the pars interarticularis in these patients,
5 of whom (83.3%; r2 = 0.416, p < 0.001) had a good
response to the injections. The abovementioned,
abnormal partial-arthrogram findings correlated with
the rate of good response to the injections. We found
iatrogenic extravasation of the injection mixture into
epidural space in 3 patients, 2 of whom had a good
response. None of the 277 patients complained of
deteriorating lower back pain after the injections.
Discussion
Lower back pain is one of the most common complaints
in clinical practice; its lifetime prevalence is estimated
at 60–90%.3,11–13 It can be classified into somatic and
radicular lower back pain. Somatic pain is aching in
quality, constant, and diffuse in position, but poorly
localized; it results from noxious stimulation of a
musculoskeletal component. Radicular pain is always
shooting in quality, and band-like in position; it results
from irritation of a spinal nerve or its roots. Diagnosis
and identification of pain source are more difficult in
somatic than radicular pain. The many sources of
somatic back pain include disks per se, vertebrae,
sacroiliac joints, zygapophyseal joints, dura mater, epi-
dural plexuses, muscles, ligaments, and thoracolum-
bar fascia.3 Pain from zygapophyseal joints is estimated
to comprise 15–40% of somatic lower back pain.3,14,15
Table 1. Patient self-reports of 10-point visual analogue scale (VAS) scores for pain versus clinical subjective judgments
of pain relief
VAS score Clinical judgment of pain relief Patient’s subjective description of pain relief
0, 1, 2 Excellent Total, or almost total, relief of symptoms
3, 4, 5 Good Obvious improvement and satisfied
6, 7, 8 Fair Slight improvement, but unsatisfied
9, 10 Poor No, or almost no, improvement of symptoms
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There are many kinds of treatments, such as medical,
herbal, physical, or chiropractic therapy, that may be
helpful for somatic lower back pain. These treatments
are also effective in many patients with lower back pain
of unknown origin. Lumbar and sacroiliac injections
can be helpful for other clinical entities, such as spon-
dyloarthropathies or sacroilitis.16 Since it is an invasive
procedure, we reserve zygapophyseal joint injections
for the late assessment of lower back pain. The present
study focused on patients with chronic somatic lower
back pain.
Zygapophyseal joints (apophyseal, facet or z-joints)
are formed by articulation of the superior articular
process of one vertebra with the inferior articular
process of the one above. Pathophysiologically, zyga-
pophyseal joints are heavily innervated areas that are
subjected to high stress and strain. Resulting tissue
damage or inflammation is likely to cause the release of
chemicals that irritate nerve endings and result in low-
er back pain.17 Possible mechanisms of zygapophyseal
lower back pain include chronic synovial and/or
capsular reaction to trauma, spinal instability, and
degenerative osteoarthritis.
Goldthwait, in 1911, was the first to suggest
lumbar zygapophyseal joints as potential sources of
lower back pain.18 Facet joint syndrome was used by
Ghormley, in 1993, to depict lower back pain of zyga-
pophyseal origin.19 In 1963, Hirsh et al reproduced
lower back pain by local injection of hypertonic
saline into the zygapophyseal joints.20 Mooney and
Robertson, in 1976, documented relief of lower back
pain by the injection of local anesthetic.1 Subsequent
investigations reported a wide range of relief rates,
from 7.7–75.0%, based on responses to a single block,
for zygapophyseal joint injections in patients with
chronic lower back pain.1,2,4–10,21–31
The use of intra-articular corticosteroids has been
suggested in several articles,1,2,5,9,26,29 regardless of
controversy. These studies reported long-term relief
rates of 18–63% for intra-articular steroids in patients
with back and referred leg pain. The clinical features or
imaging studies available for diagnosing zygapophy-
seal joint pain have not yet been explored, and lumbar
zygapophyseal joint injections for lower back pain still
require much research. Nevertheless, injection of local
anesthetics into the lumbar zygapophyseal joints, or
their nerve supply, has become accepted as the standard
for diagnosing zygapophyseal joint pain.4–10,21–29
Our study revealed that 73.6% of patients had at
least 1 week’s palliation of lower back pain after lum-
bar zygapophyseal joint injections. The subjective
intensity of pain, especially that triggered by specific
postures and/or motions, was much decreased after
the blocks. We recommended this 1 week as the
“golden period” for starting physical or other kinds of
treatment. The rate of good response in our study
group declined from 72.1% to 40.7% between the
3- and 6-week follow-up visits. This time was thought
to be the most effective for steroid injection, but this
requires further investigation. After 12 weeks’ follow-
up in the study group, the relief rate was 31.4%, which
was consistent with a prevalence of 15–40% for somatic
lower back pain of zygapophyseal joint origin.3,14,15
There seemed to be a small percentage of patients who
derived long-term benefit, and when we considered
that patients had often received several unsuccessful
treatments, it was encouraging to try lumbar zygapo-
physeal joint injections. Fifty-nine patients (28.9%)
opted to receive further aggressive radiofrequency
rhizotomy between 8 and 313 days (mean, 57.8 days)
after injection. The 2 shortest durations between
injection and rhizotomy were 8 and 14 days. These
2 patients wanted further vigorous treatment as soon
as possible, because the effects of injection were beyond
their expectations. We recommended radiofrequen-
cy rhizotomy for patients with 3 weeks’ pain relief
after zygapophyseal joint injection. We would consider
radiofrequency neurotomy as the next step for pa-
Figure 2. Spot posteroanterior film for a male patient with
spondylolysis placed in the prone position and showing the needle
positioned in the left L4–5 zygapophyseal joint (middle arrow), but
opacification of L4–5 and L5–S1 in one injection (arrows).
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tients benefiting from lumbar zygapophyseal joint
injection.32,33
All injection procedures were performed by a ra-
diologist. Peri-articular injections were made in none
of the L3–4 joints, 8.1% of the L4–5 joints, and 14.8%
of the L5–S1 joints. This revealed that, among the
lumbar joints, L5–S1 was the most difficult to inject,
perhaps because of the obtuse angle between the
spinal needle and L5–S1 zygapophyseal joint. For-
tunately, peri-articular injections did not decrease
the efficacy of articular injections. Nine percent of
patients had synovial cysts on partial arthrograms. This
was considered an underestimate, because such
arthrograms are not used for diagnosis. Most patients
with synovial cysts had significantly good responses to
the injections. We believe that synovial cysts developed
in disordered or degenerated zygapophyseal joints.
When a symptomatic zygapophyseal joint cyst is
suspected, joint injection is the first and best choice
for diagnosis and treatment.34 We found abnormal
opacification of a contiguous lumbar joint in 6 patients,
and the injected mixture flowed into bony defects in
the pars interarticularis.35–37 It was statistically significant
that 5 of these 6 patients (83.3%) had good responses
to the injections, a rate that was compatible with
previous reports for joint injection in spondylolysis.
We found 3 patients with iatrogenic extravasation
of injection mixture into the epidural space. Two of
these patients had good responses, and none had worse
symptoms after injection. The injection procedures
were safe, and none of the 277 patients had worse lower
back pain or complications after the injections.
In conclusion, our study showed lumbar zyga-
pophyseal joint injections to be useful not only for
diagnosing facet joint syndrome, but also for providing
partial and temporary palliation in patients with chronic
lower back pain. The injections also provided oppor-
tunities for patients to restart progressive physical
rehabilitation or radiofrequency rhizotomy. As a
minimally invasive, but safe, procedure, we recommend
that lumbar zygapophyseal joint injections be reserved
for the diagnosis and temporary palliation of chronic
lower back pain.
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